2025
Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure
Barbano R, Jabbari B, Sadeghi M, Ukah A, Yue E, Ifantides K, Huang N, Swope D. Incidence of Dysphagia and Comorbidities in Patients with Cervical Dystonia, Analyzed by Botulinum Neurotoxin Treatment Exposure. Toxins 2025, 17: 148. PMID: 40137921, PMCID: PMC11945862, DOI: 10.3390/toxins17030148.Peer-Reviewed Original ResearchConceptsIncidence of dysphagiaCervical dystoniaComorbid conditionsContinuous health plan enrollmentCohort entry dateRate of dysphagiaRetrospective cohort studyPre-existing dysphagiaHealth plan enrollmentRisk factors of dysphagiaFactors of dysphagiaReal-world studyPotential adverse eventsPotential risk factorsPatient-level dataReal-world analysisAdverse eventsCD patientsCohort studyComorbid neurological conditionsLongitudinal patient-level dataCD diagnosisDysphagiaDysphagia riskPatients
2024
Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.
Huntington S, Rhodes J, Manzoor B, Jawaid D, Puckett J, Emechebe N, Ravelo A, Kamal-Bahl S, Marx S, Doshi J. Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia. JCO Oncology Practice 2024, op2400220. PMID: 39705617, DOI: 10.1200/op.24.00220.Peer-Reviewed Original ResearchChronic lymphocytic leukemia treatmentChronic lymphocytic leukemiaFollow-up periodFrontline settingLymphocytic leukemiaTreatment patternsFollow-upReal-world treatment patternsMedian time to discontinuationBruton tyrosine kinase inhibitorAnti-CD20 monotherapyPatients discontinued treatmentMonths of treatmentTime to discontinuationTyrosine kinase inhibitorsReal-world studyPatient-monthsBTKiTreatment optionsVenetoclaxKinase inhibitorsPatientsAll-causeBcl-2MonthsCriteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America
Strober B, Zhong Y, Sima A, Beeghly A, Eckmann T, Balagula E, Zhuo J, Lebwohl M. Criteria for Identifying Candidates for Systemic Psoriasis Treatment in the Real World: Application of the International Psoriasis Council Guidelines in Patients in North America. Journal Of Psoriasis And Psoriatic Arthritis 2024, 10: 22-27. PMID: 39583219, PMCID: PMC11583168, DOI: 10.1177/24755303241302070.Peer-Reviewed Original ResearchBody surface areaInternational Psoriasis CouncilSystemic therapySystemic psoriasis treatmentsDisease severity criteriaTopical therapyPsoriasis treatmentTherapy candidatesCorEvitas Psoriasis RegistrySystemic therapy initiationTreatment-naive patientsSeverity criteriaReal-world studyCross-sectional studyDisease severity indicatorsPatient-reported outcome measuresPlaque psoriasisPsoriasis RegistryTherapy initiationSystemic treatmentRegistry visitPASI scoreClinical characteristicsClinical decision-makingPsoriasis severityEffectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset
Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Damoctocog Alfa Pegol to Treat Patients With Hemophilia A Enrolled in the ATHNdataset. European Journal Of Haematology 2024, 114: 448-457. PMID: 39558414, PMCID: PMC11798759, DOI: 10.1111/ejh.14337.Peer-Reviewed Original ResearchWhy Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry
Silverberg J, Bunick C, Calimlim B, Grada A, Knapp K, Munoz B, Crawford J, Obi C, Paller A. Why Do Optimal Targets for Itch and Skin Clearance Matter in Atopic Dermatitis Treatment? Insights from TARGET-DERM AD Registry. SKIN The Journal Of Cutaneous Medicine 2024, 8: s461. DOI: 10.25251/skin.8.supp.461.Peer-Reviewed Original ResearchPatient-reported outcomesTreat-to-target recommendationsSkin clearanceAtopic dermatitisOptimal treatmentSkin severityNRS-sleepSkin lesionsNRS painOptimal patient outcomesPartial improvementPatient outcomesNear-complete resolutionAtopic dermatitis treatmentReal-world studyMinimal itchingVIGA-ADOptimal treatment targetsEczema/atopic dermatitisDLQI 0/1Logistic regression modelsCross-sectional analysisItch severityOdds ratioDermatitis treatmentReal-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Doshi J, Li P, Geng Z, Lei X, Pettit A, Armstrong K, Huntington S, Lin J. Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer. Blood 2024, 144: 786-786. DOI: 10.1182/blood-2024-203410.Peer-Reviewed Original ResearchInsurance typeBlood cancerMedicare patientsCommercial insuranceStep therapyFormulary coverageNationwide sample of patientsPrior authorizationTreatment plan changesDelayed treatment initiationMonths pre-indexOdds of rejectionLonger treatment durationLife-extending therapyReal-world studyOral anticancer medicationsSample of patientsBlood cancer patientsPatient ageClinical characteristicsTreatment initiationReal-world analysisBrand-nameRetrospective analysisPre-indexReal-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Zeidan A, Zhao R, Pierre-Victor D, Wang Y, Tepsick J, Lan Z, Salimi T. Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents. Blood 2024, 144: 5189-5189. DOI: 10.1182/blood-2024-205495.Peer-Reviewed Original ResearchAML-free survivalTreated with hypomethylating agentsOral hypomethylating agentsHypomethylating agentsMyelodysplastic syndrome patientsMyelodysplastic syndromeDEC-CClinical characteristicsMDS diagnosisNext treatmentMonths median follow-upRisk of AML transformationHigh-risk myelodysplastic syndromeReal-world treatment outcomesTreatment of adult patientsHypomethylating agent treatmentKaplan-Meier survival analysis methodMedian follow-upCox regression analysisReal-world studyAML transformationHMA therapyOral decitabineECOG 0Electronic health record databaseThe Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy
Patel V, Park S, Zhong Y, Sima A, Zhuo J, Roberts-Toler C, Becker B, Hovland S, Strober B. The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy. Psoriasis Targets And Therapy 2024, 14: 167-174. PMID: 39624651, PMCID: PMC11610380, DOI: 10.2147/ptt.s478352.Peer-Reviewed Original ResearchPatient-reported disease burdenVisual analog scaleBiologic therapyPlaque psoriasisDisease burdenOdds ratioInitiation of biologic therapyQuality of lifeCorEvitas Psoriasis RegistryNonbiologic systemic therapyDisease severityPatient-reported burdenMultivariate logistic regression modelDermatology Life Quality IndexDays of enrollmentReal-world studyWork Productivity and Activity Impairment QuestionnaireLife Quality IndexPhysician-rated disease severityTherapy-naiveBiologic-naiveHealth-related quality of lifePsoriasis RegistrySystemic therapySkin painDocetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study
Patrikidou A, Saieva C, Lee-Ying R, Nuzzo P, Zarif T, McClure H, Davidsohn M, Eid M, Spinelli G, Catalano F, Cremante M, Fotia G, Rossetti S, Valenca L, Vauchier C, Ottanelli C, Andrade L, Gennusa V, Mestre R, Fornarini G, Pignata S, Procopio G, Santini D, Ravi P, Sweeney C, Heng D, De Giorgi U, Fizazi K, Russo A, Francini E, Group S. Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study. Clinical Genitourinary Cancer 2024, 22: 102230. PMID: 39461026, DOI: 10.1016/j.clgc.2024.102230.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerAndrogen receptor signaling inhibitorsCastration-resistant prostate cancerAbiraterone acetateOverall survivalProstate cancerElderly patientsSignaling inhibitorsCohort of consecutive patientsSecond-line therapyStandard first-lineReal-world studySecond-lineConsecutive patientsTreatment toxicityFirst-lineD. CONCLUSIONSPatient comorbiditiesIdentified patientsRetrospective designToxicity outcomesD groupInternational cohortPatientsNo differenceReal-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries
Lee C, Yoo C, Hong J, Park J, Kim J, Tai D, Kim H, Korphaisarn K, Tanasanvimon S, Chen S, Kim J, Kim I, Kim M, Choo J, Oh S, Chen C, Bae W, Kim H, Huh S, Yen C, Park S, Lee D, Chan L, Kang B, Kang M, Sundar R, Choi H, Chan S, Chon H, Lee M. Real-World Study of Systemic Treatment after First-Line Atezolizumab plus Bevacizumab for Hepatocellular Carcinoma in Asia-Pacific Countries. Liver Cancer 2024, 1-15. DOI: 10.1159/000540969.Peer-Reviewed Original ResearchFirst-line atezolizumabProgression-free survivalImmune checkpoint inhibitorsTyrosine kinase inhibitorsSecond-line regimensOverall survivalHepatocellular carcinomaSecond-line progression-free survivalSecond-line tyrosine kinase inhibitorsPatients treated with tyrosine kinase inhibitorsAssociated with improved OSImmune checkpoint inhibitor combinationsImmune checkpoint inhibitor useMedian progression-free survivalLow tumor burdenAdvanced hepatocellular carcinomaFirst-line regimenReal-world studyCheckpoint inhibitorsTumor burdenSystemic treatmentAtezolizumabBevacizumabRetrospective studyLenvatinibSix-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 11: 451-464. PMID: 38914857, PMCID: PMC11365873, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world studyReal-World Evidence of Automated Insulin Delivery System Use
Considine E, Sherr J. Real-World Evidence of Automated Insulin Delivery System Use. Diabetes Technology & Therapeutics 2024, 26: 53-65. PMID: 38377315, PMCID: PMC10890954, DOI: 10.1089/dia.2023.0442.Peer-Reviewed Original ResearchConceptsGlucose management indicatorAid useRetrospective real-world studyMode of insulin deliveryGlycemic benefitsFollow-up periodTrial findingsFood and Drug AdministrationStandard of careReal-world studyInsulin deliveryType 1 diabetesNonpregnant individualsPivotal trialsRetrospective analysisPrimary outcomeHemoglobin A1cConclusion:</i></b>Drug AdministrationInclusion criteriaHbA1cGlycemic outcomesSystematic reviewResults:</i></b>Target rangeMulticenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Palomba M, Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation And Cellular Therapy 2024, 30: s40-s41. DOI: 10.1016/j.jtct.2023.12.071.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR/R large B-cell lymphomaLarge B-cell lymphomaCenter for International Blood and Marrow Transplant ResearchCytokine release syndromeDuration of responseLiso-celData cutoffRisk of cytokine release syndromeCAR-T cell productsDuration of response rateHigh-risk disease featuresMedian duration of responseReal-world population of patientsB-cell lymphomaTreated with corticosteroidsCAR+ T cellsMarrow Transplant ResearchT cell productionStudy of US patientsPopulation of patientsOne-time infusionReal-world populationReal-world studyCellular therapy registry
2023
Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS
Dai M, Dou X, Chen M, Yang J, Long J, Lin Y. Strong opioids-induced cardiac, neurologic, and respiratory disorders: a real-world study from 2004 to 2023 based on FAERS. Naunyn-Schmiedeberg's Archives Of Pharmacology 2023, 397: 4105-4121. PMID: 38032491, DOI: 10.1007/s00210-023-02844-4.Peer-Reviewed Original ResearchAcute adverse drug reactionsEmpirical Bayesian geometric meanAdverse eventsSystem organ classReporting odds ratioProportional reporting ratioAdverse Event Reporting System databaseFDA Adverse Event Reporting System (FAERS) databaseSevere cancer painAdverse drug reactionsNervous system disordersReal-world studyUS FDA Adverse Event Reporting System (FAERS) databaseReporting System databasePostoperative analgesiaCancer painRespiratory depressionChronic painToxic leukoencephalopathyGeneral anesthesiaMediastinal diseaseDrug reactionsMediastinal disordersOdds ratioRespiratory disordersEfficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Iqbal M, Jagadeesh D, Chavez J, Khurana A, Rosenthal A, Craver E, Epperla N, Li Z, Isufi I, Awan F, Dholaria B, Maakaron J, Sandoval-Sus J, Mishra R, Saha A, Annunzio K, Bhaskar S, Sumransub N, Fijalka A, Ivanov S, Lin Y, Kharfan-Dabaja M. Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy. Bone Marrow Transplantation 2023, 59: 211-216. PMID: 37973893, DOI: 10.1038/s41409-023-02148-4.Peer-Reviewed Original ResearchCAR-T therapyChimeric antigen receptor T-cell therapyT-cell therapyR LBCLT therapyMedian numberResponse rateCAR-T infusionEfficacy of CD19Limited clinical activityComplete response rateCAR-T productsDuration of responseOverall response rateMulti-center studyReal-world studyMedian followR diseaseMedian durationSystemic therapyMedian timeLoncastuximab tesirineAxicabtagene ciloleucelCD19-CARClinical activity6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. 6-Month Real World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. SKIN The Journal Of Cutaneous Medicine 2023, 7: s232. DOI: 10.25251/skin.7.supp.232.Peer-Reviewed Original ResearchPhenotyping Self-Reported Health Profiles in Octogenarians and Nonagenarians After Percutaneous Coronary Intervention: A Latent Profile Analysis
Instenes I, Breivik K, Borregaard B, Larsen A, Allore H, Bendz B, Deaton C, Rotevatn S, Norekvål T, investigators C. Phenotyping Self-Reported Health Profiles in Octogenarians and Nonagenarians After Percutaneous Coronary Intervention: A Latent Profile Analysis. Heart Lung And Circulation 2023, 32: 1321-1333. PMID: 37925313, DOI: 10.1016/j.hlc.2023.09.004.Peer-Reviewed Original ResearchConceptsPercutaneous coronary interventionPoor health profileBetter health profileSelf-reported healthLow exercise levelsHealth profileCoronary interventionExercise levelsOlder adultsLow alcohol intakeLogistic regression analysisReal-world studyDifferent health outcomesMultinomial logistic regression analysisPatient characteristicsAlcohol intakeHealth outcomesHealth statusOctogenariansOlder ageNonagenariansMost participantsMonthsRegression analysisStandardised measuresReal-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset
Chandler M, Charlet J, Moulton T, Recht M. Real-World Data on Hemophilia a Patients Transitioning from Bay 81-8973 to Bay 94-9027 and from Bay 14-2222 to Bay 81-8973 and then to Bay 94-9027 in the Athndataset. Blood 2023, 142: 5479. DOI: 10.1182/blood-2023-188995.Peer-Reviewed Original ResearchData cut-offAnnualized bleeding rateFrequent dosing regimensSevere hemophilia ARecombinant factor VIIIBleeding rateStandard half-lifeHemophilia ADosing regimensFrequent regimensAnnual joint bleeding rateAnnualized spontaneous bleeding rateJoint bleeding rateSpontaneous bleeding rateHemophilia A patientsCut-offTreated with BAYTotal bleeding rateReal-world studyHalf-lifeA patientsFrequent infusionsMild diseaseTherapeutic burdenSub-analysisReal-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study
De Nigris E, Cheng W, Sarpong E, Leng S, Farooqui M, Agu U, Catillon M, Lejeune D, Downes N, Matay L, Duh M, Huntington S. Real-World Patterns of Targeted Therapy Use in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the United States: A Longitudinal Study. Blood 2023, 142: 6523. DOI: 10.1182/blood-2023-178660.Peer-Reviewed Original ResearchB-cell lymphoma-2 inhibitorBruton tyrosine kinase inhibitorsProportion of patientsCLL/SLLSmall lymphocytic lymphomaTyrosine kinase inhibitorsLymphocytic lymphomaNew agentsChronic lymphocytic leukemia/small lymphocytic lymphomaMedian age 73 yearsOptum Clinformatics DataMart databaseClinformatics DataMart databaseEnd of eligibilityObservation periodThird of patientsAge 73 yearsClaims-based algorithmChronic lymphocytic leukemiaTreatment classesReal-world studyNovel Bruton's tyrosine kinase inhibitorEligible patientsIndex dateAdult patientsTargeted agentsMulticenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US)
Crombie J, Nastoupil L, Andreadis C, Isufi I, Hunter B, Winter A, Hess B, Barta S, Frigault M, Palomba M, Grover N, Jain M, Moyo T, Patel S, Pophali P, Bernasconi D, Parrilla C, Kitali A, Liu F, Gharibo M, Pasquini M. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood 2023, 142: 104. DOI: 10.1182/blood-2023-180242.Peer-Reviewed Original ResearchImmune effector cell-associated neurotoxicity syndromeR LBCLLarge B-cell lymphomaCytokine release syndromeProgression-free survivalDuration of responseReal-world clinical effectivenessHigh-grade B-cell lymphomaLiso-celInternational Prognostic IndexB-cell lymphomaOverall survivalSystemic therapyReal-world studyData cutoffPostmarketing studyMedian timeClinical effectivenessClinical studiesFavorable benefit/risk profileReal-world settingMedian DORMedian progression-free survivalBenefit/risk profileCAR T-cell products
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply